Piper Sandler analyst Edward Tenthoff raised the firm’s price target on Sutro Biopharma to $18 from $16 and keeps an Overweight rating on the shares. The company updated Phase I dose-expansion data on luvelta tazevibulin in ovarian cancer showing an overall response rate of 37.5% and median progression free survival of 6.1 months, Tenthoff tells investors in a research note.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on STRO:
- Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer
- Sutro Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Sutro Biopharma to Provide Data Update on STRO-002 and Plans for Registrational Path Forward in Advanced Ovarian Cancer
- Sutro Biopharma, Vaxcyte in development option grant deal for cell-free extract
- Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract
